Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Pharm. 2019 May 30;16(7):3024–3039. doi: 10.1021/acs.molpharmaceut.9b00263

Table 1.

Biophysical Characteristics of FAF, FAF–Rapa, and Rhodamine-Labeled FAF–Rapa

Rh (nm)c at
label formulation compositiona MW (kDa)b 20 °C 37 °C
FAF FKBP–G(VPGAG)192–FKBP 96.6 8 ± 1 8 ± 1
FAF–Rapa Rapa/FKBP–G(VPGAG)192–FKBP/Rapa 98.3 9 ± 2 8 ± 0.3
Rho–FAF–Rapa rhodamine–[Rapa/FKBP–G(VPGAG)192–FKBP/Rapa] 98.8 9 ± 1 7 ± 0.3
a

FKBP amino acid sequence: GVQVETISPGDGRTFPKRGQT CVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE. G(VPGAG)192Y is the amino acid sequence of the elastin-like polypeptide, A192.

b

Expected molecular weights for FAF–Rapa and Rho–FAF–Rapa were reported based on observed 1:1 molar ratios of Rapa to FKBP and the rhodamine-labeling ratio.

c

Hydrodynamic radii of each formulation (of 10 μM, PBS) were determined in triplicate by DLS (Mean ± SD).